Skip to content

H.R. 3503 · 118th Congress (2023–2025)

NIH Clinical Trial Diversity Act of 2023

This bill sets out requirements to increase the diversity of clinical trial participants and requires other activities to foster participation in clinical trials.

As a condition of approval from the National Institutes of Health (NIH) for a clinical trial investigating a drug, device, or behavioral intervention, a sponsor's application must include certain information related to diversity in its trial, such as

  • goals for recruiting and retaining trial participants,
  • plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements, and
  • requirements for researchers and other individuals involved with the trial to complete education and training about diversity in clinical trials.

A sponsor must also annually share demographic data of clinical trial participants with the NIH. The NIH must publish on its website information about the diversity of and other information concerning the clinical trials it funds.

If a sponsor fails to meet its diversity goals or related requirements, the sponsor must develop and implement a strategic plan to increase the diversity of the clinical trial participants.

Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.

The bill also requires studies on barriers to participation in clinical trials. The Government Accountability Office must study actions taken by federal agencies to address such barriers while the NIH must study regulations that govern reimbursements of out-of-pocket expenses of and incentives for clinical trial participants.

Show official title

To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 3503’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Robin L. Kelly (D-IL-2)
Cosponsors
40 cosponsors

1 original · 39 later

1 R · 39 D

  1. Rep. Brian K. Fitzpatrick (R-PA-1)· Original · May 18, 2023
  2. Rep. Anna G. Eshoo (D-CA-16)· Later · May 31, 2023
  3. Rep. Gwen Moore (D-WI-4)· Later · May 31, 2023
  4. Del. Eleanor Holmes Norton (D-DC)· Later · May 31, 2023
  5. Rep. Debbie Wasserman Schultz (D-FL-25)· Later · Jun 12, 2023
  6. Rep. Nanette Diaz Barragán (D-CA-44)· Later · Jun 21, 2023
  7. Rep. Alma S. Adams (D-NC-12)· Later · Jul 6, 2023
  8. Rep. Yvette D. Clarke (D-NY-9)· Later · Jul 6, 2023
  9. Rep. Dean Phillips (D-MN-3)· Later · Jul 6, 2023
  10. Rep. Tony Cárdenas (D-CA-29)· Later · Jul 10, 2023
  11. Rep. Pramila Jayapal (D-WA-7)· Later · Jul 10, 2023
  12. Rep. Colin Z. Allred (D-TX-32)· Later · Jul 18, 2023
  13. Rep. William R. Keating (D-MA-9)· Later · Aug 4, 2023
  14. Rep. Sean Casten (D-IL-6)· Later · Aug 11, 2023
  15. Rep. Ted Lieu (D-CA-36)· Later · Sep 12, 2023
  16. Rep. Mark Pocan (D-WI-2)· Later · Sep 12, 2023
  17. Rep. Lisa Blunt Rochester (D-DE)· Later · Sep 26, 2023
  18. Rep. James A. Himes (D-CT-4)· Later · Sep 26, 2023
  19. Rep. Henry C. "Hank" Johnson, Jr. (D-GA-4)· Later · Sep 26, 2023
  20. Rep. Brittany Pettersen (D-CO-7)· Later · Sep 26, 2023
  21. Rep. Seth Magaziner (D-RI-2)· Later · Oct 11, 2023
  22. Rep. Bonnie Watson Coleman (D-NJ-12)· Later · Oct 11, 2023
  23. Rep. Jill N. Tokuda (D-HI-2)· Later · Oct 19, 2023
  24. Rep. Yadira Caraveo (D-CO-8)· Later · Oct 26, 2023
  25. Rep. Andy Kim (D-NJ-3)· Later · Nov 29, 2023
  26. Rep. Josh Gottheimer (D-NJ-5)· Later · Feb 29, 2024
  27. Rep. Sheila Jackson Lee (D-TX-18)· Later · Mar 26, 2024
  28. Rep. Joe Neguse (D-CO-2)· Later · Mar 29, 2024
  29. Rep. Joseph D. Morelle (D-NY-25)· Later · Apr 23, 2024
  30. Rep. Becca Balint (D-VT)· Later · May 6, 2024
  31. Rep. Mark DeSaulnier (D-CA-10)· Later · May 6, 2024
  32. Rep. Stephen F. Lynch (D-MA-8)· Later · May 6, 2024
  33. Rep. Grace F. Napolitano (D-CA-31)· Later · May 6, 2024
  34. Rep. Scott H. Peters (D-CA-50)· Later · May 6, 2024
  35. Rep. Jason Crow (D-CO-6)· Later · May 21, 2024
  36. Rep. Jennifer L. McClellan (D-VA-4)· Later · May 21, 2024
  37. Rep. Paul Tonko (D-NY-20)· Later · May 22, 2024
  38. Rep. Mary Sattler Peltola (D-AK)· Later · Jun 13, 2024
  39. Rep. Jerrold Nadler (D-NY-12)· Later · Aug 9, 2024
  40. Rep. Melanie A. Stansbury (D-NM-1)· Later · Dec 5, 2024
Policy area
Health
Subjects
  • Congressional oversight
  • Government information and archives
  • Government studies and investigations
  • Health information and medical records
  • Medical research
  • Minority health
  • National Institutes of Health (NIH)
  • Research administration and funding
  • 1 more
    • Women's health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · May 18, 2023 – May 19, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred May 18, 2023
  2. HouseHealthReferred May 19, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. NIH Clinical Trial Diversity Act of 2023

    Display title, Short title · Introduced in House

  2. To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.

    Official title · Introduced in House